Keyphrases
12-month Follow-up
66%
Ankle-brachial Index
33%
Calf muscle
33%
Critical Limb Ischemia
100%
Dose-escalation Study
33%
Hepatocyte Growth Factor
100%
Human Hepatocyte Growth Factor
66%
Human Trials
33%
Increased Dose
33%
Intramuscular Injection
33%
Non-viral
100%
Pain Severity
33%
Phase I Study
100%
Plasmid
100%
Plasmid DNA (pDNA)
33%
Randomized Controlled Trial
33%
Revascularization
33%
Severity Score
33%
TBI Severity
33%
Toe-brachial Index
33%
Tolerability
33%
Visual Analog Scale
66%
Immunology and Microbiology
Ankle
25%
Donaperminogene Seltoplasmid
100%
Hepatocyte Growth Factor
100%
Limb
100%
Muscle
25%
Plasmid
100%
Revascularization
25%
Toe
25%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
25%
Donaperminogene Seltoplasmid
100%
Hepatocyte Growth Factor
100%
Isoform
100%
Plasmid
100%
Randomized Controlled Trial
25%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
25%
Critical Limb Ischemia
100%
Donaperminogene Seltoplasmid
100%
Intramuscular Injection
25%
Plasmid DNA
25%
Randomized Controlled Trial
25%
Scatter Factor
100%
Tolerability
25%